Prognostic impact of δ-like ligand 4 and Notch1 in acute myeloid leukemia

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1503-1511

  Zhang, Jingru ^a   Ma, Daoxin ^a   Ye, Jingjing ^a   Zang, Shaolei ^a   Lu, Fei ^a   Yang, Meixiang ^a   Qu, Xun ^a   Sun, Xiulian ^a   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

like ligand 4; Acute myeloid leukemia; Angiogenesis; Notch1; Prognosis

Indexed keywords

ANGIOPOIETIN; DELTA LIKE LIGAND 4 PROTEIN; MEMBRANE PROTEIN; NOTCH1 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CYTOGENETICS; DELTA LIKE LIGAND 4 GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; NOTCH1 GENE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; ANGIOPOIETIN-2; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, NOTCH1; RECEPTOR, TIE-2; TRANSCRIPTOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84866462073     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1943     Document Type: Article

References (45)

1. Zhang Y, Tang H, Cai J, et al: Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 303: 47-55, 2011.
2. Hao CY: Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges. J Gastroenterol Hepatol 26: 4-6, 2011.
3. Shih TT, Hou HA, Liu CY, et al: Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival. Blood 113: 3161-3167, 2009.
4. Trujillo A, McGee C and Cogle CR: Angiogenesis in acute myeloid leukemia and opportunities for novel therapies. J Oncol 2012: 128608, 2012.
5. Payne SJ and Jones L: Influence of the tumor microenvironment on angiogenesis. Future Oncol 7: 395-408, 2011.
6. Ayala F, Dewar R, Kieran M and Kalluri R: Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 23: 2233-2241, 2009.
7. Hou HA, Chou WC, Lin LI, et al: Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia. Leuk Res 32: 904-912, 2008.
8. Carmeliet P and Jain RK: Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307, 2011.
9. Kip1 in acute myeloid leukemia. Leukemia 23: 251-261, 2009.
10. Schmidt T and Carmeliet P: Angiogenesis: a target in solid tumors, also in leukemia? Hematology Am Soc Hematol Educ Program 2011: 1-8, 2011.
11. Tait CR and Jones PF: Angiopoietins in tumours: the angiogenic switch. J Pathol 204: 1-10, 2004.
12. Reikvam H, Hatfield KJ, Lassalle P, Kittang AO, Ersvaer E and Bruserud O: Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opin Investig Drugs 19: 169-183, 2010.
13. Maffei R, Martinelli S, Castelli I, et al: Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 34: 312-321, 2010.
14. Keith T, Araki Y, Ohyagi M, et al: Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 137: 206-215, 2007.
15. Aguayo A, Kantarjian HM, Estey EH, et al: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95: 1923-1930, 2002.
16. de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hahlen K and Kamps WA: Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 8: 2856-2861, 2002.
17. Loges S, Heil G, Bruweleit M, et al: Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol 23: 1109-1117, 2005.
18. Schliemann C, Bieker R, Thoennissen N, et al: Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia 21: 1901-1906, 2007.
19. Wu Y, Cain-Hom C, Choy L, et al: Therapeutic antibody targeting of individual Notch receptors. Nature 464: 1052-1057, 2010.
20. Demarest RM, Dahmane N and Capobianco AJ: Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood 117: 2901-2909, 2011.
21. Leong KG and Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood 107: 2223-2233, 2006.
22. Phng LK and Gerhardt H: Angiogenesis: a team effort coordinated by notch. Dev Cell 16: 196-208, 2009.
23. Li JL and Harris AL: Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 8: 1-3, 2005.
24. Ridgway J, Zhang G, Wu Y, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444: 1083-1087, 2006.
25. Noguera-Troise I, Daly C, Papadopoulos NJ, et al: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444: 1032-1037, 2006.
26. Lobry C, Oh P and Aifantis I: Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 208: 1931-1935, 2011.
27. Lobov IB, Brooks PC and Lang RA: Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 99: 11205-11210, 2002.
28. Li JL and Harris AL: Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci 14: 3094-3110, 2009.
29. Thurston G and Kitajewski J: VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 99: 1204-1209, 2008.
30. Morrow D, Cullen JP, Cahill PA and Redmond EM: Ethanol stimulates endothelial cell angiogenic activity via a Notch- and angiopoietin-1-dependent pathway. Cardiovasc Res 79: 313-321, 2008.
31. Zhang J, Fukuhara S, Sako K, et al: Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin. J Biol Chem 286: 8055-8066, 2011.
32. Kittang AO, Hatfield K, Sand K, Reikvam H and Bruserud O: The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 341: 149-172, 2010.
33. Muller-Berndorff H, Haas PS, Kunzmann R, Schulte-Monting J and Lubbert M: Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. Ann Hematol 85: 502-513, 2006.
34. Ji M, Li J, Yu H, et al: Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia. Br J Haematol 145: 648-656, 2009.
35. Lee CY, Tien HF, Hu CY, Chou WC and Lin LI: Marrow angiogenesis- associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia. Br J Cancer 97: 877-882, 2007.
36. Ghaleb AM, Aggarwal G, Bialkowska AB, Nandan MO and Yang VW: Notch inhibits expression of the Kruppel-like factor 4 tumor suppressor in the intestinal epithelium. Mol Cancer Res 6: 1920-1927, 2008.
37. Li GH, Fan YZ, Liu XW, et al: Notch signaling maintains proliferation and survival of the HL60 human promyelocytic leukemia cell line and promotes the phosphorylation of the Rb protein. Mol Cell Biochem 340: 7-14, 2010.
38. Tohda S: Functional analysis of notch in the pathophysiology of leukemia. Rinsho Byori 57: 351-356, 2009 (In Japanese).
39. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer 116: 5676-5685, 2010.
40. Reedijk M, Odorcic S, Chang L, et al: High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530-8537, 2005.
41. Shi TP, Xu H, Wei JF, et al: Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. J Urol 180: 361-366, 2008.
42. Siekmann AF, Covassin L and Lawson ND: Modulation of VEGF signalling output by the Notch pathway. Bioessays 30: 303-313, 2008.
43. Williams CK, Li JL, Murga M, Harris AL and Tosato G: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGFinduced endothelial cell function. Blood 107: 931-939, 2006.
44. Wakabayashi M, Miwa H, Shikami M, et al: Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase. Hematol J 5: 353-360, 2004.
45. Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102: 972-980, 2003.